WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced that it has filed, with the Securities and Exchange Commission, an amendment to its registration statements increasing the aggregate principal amount of its new money offering of 3.50% Convertible Senior Notes due 2011 from $30,000,000 to $50,000,000.
